Holen Sie sich die Stockscreener-App
0.4882
2.36%
-0.0118
Outlook Therapeutics Inc Aktie (OTLK) Neueste Nachrichten
Two reported owners share voting power over a stake above 5% in Outlook Therapeutics (OTLK). - Stock Titan
Certain Common Stock of Outlook Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 12-OCT-2026. - www.marketscreener.com
Outlook Therapeutics (Nasdaq:OTLK)Stock Analysis - Simply Wall Street
Outlook Therapeutics files CMS code application and Outlook Therapeutics stock trades at EUR 0.53 - AD HOC NEWS
Outlook Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Outlook Therapeutics at H.C. Wainwright: launch hinges on access By Investing.com - Investing.com Australia
Outlook Therapeutics at H.C. Wainwright: launch hinges on access By Investing.com - Investing.com Canada
Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand - The Manila Times
Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand - marketscreener.com
Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand - Yahoo Finance
OTLK Maintained by Ascendiant Capital -- Price Target Raised to $10.50 - GuruFocus
Outlook Therapeutics Inc. (OTLK) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Outlook Therapeutics CEO discusses LYTENAVA commercial launch By Investing.com - Investing.com Australia
Outlook Therapeutics CEO discusses LYTENAVA commercial launch By Investing.com - Investing.com Nigeria
Outlook Therapeutics CEO discusses LYTENAVA commercial launch - investing.com
Outlook Therapeutics CEO discusses LYTENAVA commercial launch By Investing.com - Investing.com Canada
Outlook Therapeutics CEO discusses LYTENAVA commercial launch By Investing.com - Investing.com UK
Only one FDA-approved eye medicine of its type exists in the U.S. It’s LYTENAVA. - Stock Titan
AMZN: Amazon.com Inc Latest Stock Price, Analysis, News and Trading Ideas - stocktwits.com
People on the Move: Kevin Lundquist Named Chief Financial Officer of Outlook Therapeutics - BioBuzz
CFO at Outlook Therapeutics (NASDAQ: OTLK) gets 500,000 hiring options - Stock Titan
Outlook Therapeutics (NASDAQ: OTLK) CFO reports zero insider holdings - stocktitan.net
Outlook Therapeutics Announces CFO Transition and Board Change - The Globe and Mail
Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™ - Sahm
Outlook Therapeutics Names Kevin Lundquist CFO Ahead of Lytenava U.S. Launch - VisionMonday.com
Outlook Therapeutics Names Kevin Lundquist CFO Ahead of Lytenava U.S. Launch - visionmonday.com
Outlook Therapeutics appoints Kevin Lundquist as CFO as Lawrence Kenyon to depart - TradingView
Outlook Therapeutics Appoints Kevin Lundquist as Chief - GlobeNewswire
Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference - marketscreener.com
Outlook Therapeutics hires a CFO for its only FDA-approved eye version of bevacizumab - stocktitan.net
Outlook Therapeutics(OTLK) Stock Options Chain | Quotes & News - Moomoo
Nasdaq Futures Lead US Premarket Rally As Iran Ceasefire Reports Ease Fears Ahead Of Big Tech Earnings: Why NVDA, ORCL, SPCX, XOM, OTLK Are In Focus - Stocktwits
Outlook Therapeutics (OTLK) investor held to 9.99% cap - Stock Titan
Outlook Therapeutics Inc (OTLK) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Outlook Therapeutics(OTLK) Stock Options Chain | Quotes & News - Moomoo
Outlook Therapeutics, Inc. 2026: Revenue $8.7K, EPS ($0.15) — 10-Q Summary - TradingView
Outlook Therapeutics (OTLK) wins FDA exclusivity but holds limited cash - Stock Titan
Brookline Capital cuts Outlook Therapeutics stock price target on model update - Investing.com
Brookline Capital cuts Outlook Therapeutics stock price target on model update - Investing.com
Outlook Therapeutics(OTLK) Stock Options Chain | Quotes & News - Moomoo
Outlook Therapeutics delays quarterly SEC filing - TipRanks
META_TITLE_QUOTE - Yahoo Finance
OTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales Ramp - Yahoo Finance
OTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales Ramp - Zacks Investment Research
Outlook Therapeutics Insider Bought Shares Worth $2,499,999, According to a Recent SEC Filing - marketscreener.com
Outlook Therapeutics Insider Bought Shares Worth $2,499,999, According to a Recent SEC Filing - moomoo.com
Outlook Therapeutics, Inc. SEC Filing (Aug 17, 2026) | OTLK NT 10-Q - Stock Titan
Outlook Therapeutics Posts Q3 Financials, Raises Funds for Lytenava Launch - visionmonday.com
Outlook Therapeutics Inc (OTLK) Stock News Today - TradingKey
MSN Money - MSN
4.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):